Glenmark Pharmaceuticals Europe Ltd has entered into a strategic development and licensing agreement with Celon Pharma SA to develop and market a generic version of GSK’s Seretide Accuhaler product – fluticasone and salmeterol dry powder inhaler in Europe upon commercialisation. Celon, on the other hand, shall receive an upfront payment, followed by certain milestone payments during various stages of the product’s development from Glenmark, including royalties on sales. The distribution agreement was concluded for a period of 10 years, with an option of a two-year extension.